Retatrutide is a next-generation investigational peptide that acts as a triple agonist of the GLP-1, GIP, and glucagon receptors
Cerebral effects of ammonia in liver disease: current hypotheses
This belief often discourages the use of other, more readily accessible forms of produce, which does not help address the global inadequacy in fruit and vegetable consumption
Conclusion The field of anti-obesity drug development is rapidly evolving, with new therapies emerging that offer the potential for more effective and personalised weight management
Clinical Uses The most prominent FDA-approved drug leveraging GIP biology is tirzepatide (trade name Mounjaro for T2DM
Its levels decline naturally with age, and this decline is accelerated by chronic conditions including HIV/AIDS, cancer, type 2 diabetes, Parkinson's disease, and hepatitis